India

COVID-19 Coronavirus Pandemic – Latest Media Coverage

Serum Institute of India

Indian biotechnological company, vaccine manufacturer

Serum Institute of India ▸ Facts ▸ Comments ▸ News ▸ Videos

Serum Institute of India: Indian biotechnological company, vaccine manufacturer

Serum Institute of India is a manufacturer of immunobiological drugs including vaccines in India. It was founded by Cyrus Poonawalla in 1966. The company is a subsidiary of the holding company Poonawalla Investment and Industries.

0 shares	Share Tweet Save Post Send



Covid: 3 vaccines at clinical trial stage in India; SII’s phase 3 trial soon Director General of the Indian Council of Medical Research (ICMR), Dr Balram Bhargava said three vaccine candidates are at different clinical trial stages in India. Covid-19 vaccine candidates being.. Credit: HT Digital Content Duration: 01:19Published 2 weeks ago

Covid update: 1,500 crore vaccine doses; onion export ban; Oct-Nov warning From the CEO of the world's largest vaccine manufacturer commenting on the possible timeline of the final vaccine reaching every person on the planet, to the World Health Organisation warning that the.. Credit: HT Digital Content Duration: 02:18Published 2 weeks ago

Covid: Serum Institute begins human trials, 5 volunteers given first shot The Phase II human clinical trial of the Oxford COVID-19 vaccine candidate, being manufactured by the city-based Serum Institute of India (SII), began at a medical college and hospital here on.. Credit: HT Digital Content Duration: 02:01Published on August 26, 2020

Covid \| 'Oxford vaccine's late stage trials to start in a week in India': ICMR At present country has three Indian COVID-19 vaccines which are in different phases of clinical testing, said Indian Council of Medical Research (ICMR) Director General Dr Balram Bhargava on Tuesday... Credit: HT Digital Content Duration: 06:42Published on August 4, 2020

COVID-19: Oxford vaccine's late stage trials to start in a week in India, says ICMR Director General of Indian Council of Medical Research, Dr Balram Bhargava on August 04 stated that Oxford vaccine, being manufactured by Serum Institute of India, got approval for phase 2 and 3.. Credit: ANI Duration: 02:24Published on August 4, 2020

COVID update: India to start late stage trials of Oxford vaccine, Shivraj tests positive again The Drugs Controller General of India (DCGI) has given approval to Serum Institute of India (SII), Pune, to conduct Phase II and III clinical trials of Oxford University. According to the World Health.. Credit: ANI Duration: 01:38Published on August 3, 2020

You Might Like

Serum to make extra 100 million vaccine doses Serum Institute of India will produce up to an additional 100 million COVID-19 vaccine doses for India and low and middle-income countries in 2021.The company made this announcement taking forward the.. IndiaTimes - Published 1 day ago
I wish government's Covid vaccine strategy was 'Mann ki Baat': Rahul Gandhi Gandhi's tweet came after Prime Minister Narendra Modi aired his monthly 'Mann ki baat' programme on the All India Radio (AIR). Along with his comment, Gandhi shared a news report regarding Serum.. IndiaTimes - Published 4 days ago
Serum Institute CEO lauds PM Narendra Modi's COVID-19 vaccine vision day after challenging Centre on pandemic response It is to be noted that the Serum Institute of India is all set to begin phase three trials of the Covishield Vaccine developed by AstraZeneca and Oxford University at Sassoon General Hospital in Pune. DNA - Published 4 days ago

Can Centre procure Rs 80,000 crore to buy, distribute COVID-19 vaccine across India? SII CEO Adar Poonawalla asks On September 16, the Drugs Controller General of India (DCGI) allowed the Serum Institute of India (SII) to restart its phase two and three clinical trials for the Oxford-AstraZeneca COVID-19 vaccine. DNA - Published 5 days ago
Phase 3 human clinical trial of Oxford vaccine begins in Pune The phase-III human clinical trial of the Covid-19 vaccine being developed by Oxford University, and manufactured by the Serum Institute of India (SII), began at the state-run Sassoon General Hospital.. IndiaTimes - Published 1 week ago
Serum Institute of India to resume Oxford-AstraZeneca COVID-19 vaccine trials; gets DCGI nod The Drugs Controller General of India (DCGI) has allowed the Serum Institute of India (SII) to resume its phase two and three clinical trials for the Oxford-AstraZeneca COVID-19 vaccine. DNA - Published 2 weeks ago

DCGI orders Serum Institute of India to suspend recruitment for Oxford Covid-19 vaccine trials IndiaTimes - Published 3 weeks ago
India will have 'approved' Covid vaccine by 2021 Q1: Report India is on course to have an "approved" vaccine within the first quarter of calendar year 2021 and Pune- based Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, is.. IndiaTimes - Published on August 28, 2020
Oxford Covid vaccine trail: Vital signs of volunteers normal, says doctor Two men, aged 32 and 48, were given the first shot of the 'Covishield' vaccine, being manufactured by Pune-based Serum Institute of India (SII), at Bharti Vidyapeeth's Medical College and Hospital on.. IndiaTimes - Published on August 27, 2020
Covid-19 vaccine: Govt panel meets representatives of leading domestic manufacturers The national expert group on vaccine administration for Covid-19 met representatives of leading domestic manufactures, including Serum Institute of India, Bharat Biotech and Zydus Cadila, on Monday to.. IndiaTimes - Published on August 17, 2020

Serum Institute of India enters into partnership to accelerate manufacture, delivery of Covid vaccines for India The Serum Institute of India (SII) has entered into a new landmark partnership with Gavi, the Vaccine Alliance and the Bill and Melinda Gates Foundation, to accelerate the manufacture and delivery of.. IndiaTimes - Published on August 7, 2020
DCGI nod to Serum Institute of India for phase 2 & 3 clinical trials of Oxford Covid-19 vaccine The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India for conducting phase 2 and 3 human clinical trials of the Oxford University's Covid-19 vaccine candidate in.. IndiaTimes - Published on August 3, 2020
Coronavirus vaccine: DCGI gives nod to Serum-Oxford for phase 2, 3 clinical trials in India DCGI has allowed the Serum Institute of India to conduct phase 2 and 3 human clinical trials in India on the potential COVID19 vaccine. DNA - Published on August 3, 2020	Panel recommends permission to Serum Institute for phase 2, 3 human clinical trials of Oxford vaccine candidate A subject expert committee on Covid-19 on Friday recommended to the country's drug regulator that permission be granted to Serum Institute of India (SII) for conducting the second and third phases of.. IndiaTimes - Published on July 31, 2020
Seven Indian pharma players race to develop Covid-19 vaccine At least seven Indian pharma companies are working to develop a vaccine against coronavirus as they join global efforts to find a preventive to check the spread of the deadly virus that has already.. IndiaTimes - Published on July 19, 2020	No proof MMR vaccination offers protection against Covid-19, says Serum Institute IndiaTimes - Published on July 13, 2020
How one Indian company could be world's door to a COVID-19 vaccine If the world is to gain access to a vaccine for COVID-19, there's a good chance it will pass through the doors of Serum Institute of India. Reuters India - Published on May 22, 2020	Covid-19: Pune co plans to start vaccine production next month Pune-based Serum Institute, credited with affordable and innovative therapies like pneumonia and dengue monoclonal vaccines, plans to price the proposed Covid vaccine at around Rs 1,000 per dose in.. IndiaTimes - Published on April 26, 2020